Clear Cell Renal Cell Carcinoma

Our study demonstrated, downregulation of hsa-miR-200b-3p in ccRCC holds promise as a potential diagnostic biomarker and its identified target NDUFS1 as an independent prognostic biomarker for patients with ccRCC. These findings need to be validated in a large cohort of patients with RCC.

Our findings reveal an intrinsic SLFN11-dependent vulnerability in ccRCC that synergizes with alkylating agents to induce an acquired PARP-1 dependency, thereby sensitizing BRCA1/2-WT tumors to PARP inhibition. Therefore, this work uncovers a potential therapeutic strategy for targeting SLFN11-high kidney cancers.

Adjuvant immunotherapy has transformed the management of high-risk resected ccRCC, with pembrolizumab demonstrating improvements in DFS and OS...Additional biomarkers including sarcomatoid differentiation, specific genomic drivers (PBRM1, BAP1, VHL), circulating tumor DNA, epigenetic signatures, and systemic inflammatory markers, provide complementary insights into tumor biology and host-tumor interaction. Although none of these biomarkers are currently validated for routine clinical decision-making, integrative models combining clinicopathologic and molecular features may enable more precise selection of patients for adjuvant immunotherapy and help reduce overtreatment in localized ccRCC.

P2, N=62, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: May 2026 --> Jan 2027

Preliminary evidence also suggests that DNER overexpression may be associated with enhanced sensitivity of ccRCC cells to the PARP inhibitor Olaparib, although the underlying mechanism requires further investigation. In conclusion, DNER drives ccRCC progression by coupling glycolytic reprogramming with immunosuppressive microenvironment formation via the JAK2/STAT3 signaling axis, and may represent a potential therapeutic target for ccRCC.

Together, these findings reveal that GPR132 signaling promotes ccRCC by sustaining mitochondrial integrity and elevating lactate import. The crosstalk between lactate and tumor cells is a metabolic vulnerability that can be disrupted by targeting GPR132, providing a potential treatment strategy for ccRCC.

However, the histopathology of the pancreatic mass revealed metastatic ccRCC. This case highlights that RCC can cause extremely late recurrences and rarely mimics neuroendocrine tumors (NETs) due to SSTR expression.

TLN1 was markedly overexpressed in ccRCC tissues and cell lines, and its knockdown significantly reduced proliferation, migration, and colony formation in vitro, supporting a pro-tumorigenic function. This study uncovers platelet-related AS dysregulation in ccRCC and identifies TLN1 as a promising biomarker and therapeutic target, offering new insights into ccRCC pathogenesis and treatment strategies.

Our study defines CD8⁺ILT2⁺ TILs as an untapped effector population with potential antitumor activity and a promising therapeutic target in ccRCC. These findings offer new insights into TIL functional diversity and pave the way for innovative immunotherapies beyond conventional ICIs.

P1, N=30, Recruiting, Canadian Cancer Trials Group | Not yet recruiting --> Recruiting

This nine-BRM prognostic model serves as a potential prognostic stratification tool that may complement existing clinical parameters in evaluating the outcomes of KIRC patients.

P2, N=18, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting